What is this study trying to find out about 22q11.2 deletion syndrome?

This study aims to identify early behavioral signs that may indicate the start of psychotic disorders in children with 22q11.2 deletion syndrome. Researchers want to understand how social and cognitive changes relate to psychotic symptoms in children aged 4 to 13 years. The study is led by Hôpital le Vinatier and focuses on improving knowledge around this genetic condition.

Who may be eligible for this 22q11.2 deletion syndrome clinical trial?

Children aged 4 to 13 years who have 22q11.2 deletion syndrome or no developmental disease may be eligible. Participants must understand French and should not have an intellectual deficiency according to DSM 5 criteria or be taking medications that affect brain function. Please review eligibility criteria for more details.

Is there any cost to participate in this 22q11.2 deletion syndrome clinical trial?

Study-related care, including all testing and trial visits, is provided at no cost. However, personal travel or other expenses may vary and are not guaranteed to be covered.

Actively Recruiting

Phase Not Applicable

Age: 4Years - 13Years

All Genders

Healthy Volunteers

ID04639388

Characterize Behavioral Early Signs of Psychotic Disorders in Children With 22q11.2 Deletion Syndrome Aged 4 to 13 Years

Led by Hôpital le Vinatier · Updated on 2025-07-30

Participants Needed

Research Sites

13 weeks

Total Duration

AI-Summary

What this Trial Is About

Researchers are investigating the early behavioral signs that may signal the onset of psychotic disorders in children with 22q11.2 deletion syndrome 22q11.2DS, a common genetic condition linked to an increased risk of schizophrenia. This study aims to better understand social cognitive processes and behavioral changes that could lead to psychotic symptoms in children aged 4 to 13 years, including those without developmental diseases for comparison. The study involves two groups children with 22q11.2DS and children without developmental disorders, both aged 4 to 13 years. Participants will complete neuropsychological tests, questionnaires, and experimental tasks to assess attention, behavior, gaze direction, and facial expression recognition. These activities include well-established batteries such as TEA-Ch, Reys Tangled Lines Test, and NEPSY II, performed during a single study visit. During participation, children will undergo various assessments including anxiety-related emotional disorder screening and facial expression recognition tasks. Researchers will also measure sustained hearing attention, reaction times, and other cognitive functions. The study does not involve any drug treatments and participation includes behavioral testing and questionnaires completed by the childrens legal representatives. The entire study visit occurs on one day, and the research will continue through September 2026 to gather comprehensive data from enrolled children.

CONDITIONS

Brief Title

Understanding of Psychotic Disorders in Children With 22q11.2DS

Who Can Participate

Age: 4Years - 13Years

All Genders

Healthy Volunteers

Eligibility Criteria

You may qualify if you...

Diagnosis of 22q11.2 deletion syndrome or no developmental disease
Aged from 4 to 13 years old
Ability to understand and communicate in French

You will not qualify if you...

Diagnosis of intellectual deficiency according to DSM 5 criteria
Use of medication for a physical condition that might affect brain function

Research Team

Caroline DEMILY, MD PH

Véronique VIAL

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here